2 Weight-Loss Stocks That Could Rocket Higher This Year

Upcoming clinical trial results could push these stocks through the roof before 2024 is finished.It's hard to overstate just how successful weight-management treatments have been over the past couple of years. Sales of semaglutide, the drug that Novo Nordisk (NVO -2.99%) markets as Ozempic and Rybelsus for diabetes, and as Wegovy for weight management, have soared to an annualized $27.9 billion.Semaglutide first earned approval from the Food and Drug Administration (FDA) back in 2017. A much younger treatme ...